Rate My Professor Dmitri Simberg

Dmitri Simberg is a Professor in the Department of Pharmaceutical Sciences at the Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, where he also serves as Co-Director of the Colorado Center for Nanomedicine and Nanosafety. He directs the Translational Bio-Nanosciences Laboratory, which employs multidisciplinary approaches including biochemistry, molecular biology, in vivo perfusion, imaging, intravital microscopy, serum biochemistry, in vivo pharmacology, and population studies in healthy individuals and patients. Simberg earned his B.Pharm. and Ph.D. in Biochemistry from The Hebrew University of Jerusalem, Israel. Following his doctoral studies, he completed postdoctoral fellowships at the Sanford-Burnham Medical Research Institute in La Jolla, California, and the Department of Radiology at the University of California San Diego. He joined the University of Colorado Anschutz Medical Campus as an Assistant Professor in 2013 and progressed to the rank of full Professor.

Simberg's research specializes in drug delivery systems, immune recognition of nanoparticles, particularly complement system activation by engineered nanomaterials, mechanisms of nanoparticle deposition in skin, tumors, and bone marrow metastases, and the design of safe translational nanotherapeutics. His laboratory investigates iron oxide nanoworms for MRI contrast and cancer therapy, drug delivery and in vivo sensors using engineered red blood cells, and circulating tumor cells and microparticles from cancer patients' blood via engineered gas microbubbles. Key publications include "Biomimetic amplification of nanoparticle homing to tumors" (Proceedings of the National Academy of Sciences, 2007; 666 citations), "Enhanced immunocompatibility and hemocompatibility of nanomedicines by complement inhibitors" (Science Advances, 2025), "PEGylation technology: addressing concerns, moving forward" (Drug Delivery and Translational Research, 2025), "Perspectives on complement and phagocytic cell responses to nanoparticles" (Journal of Controlled Release, 2023), and "Dendrimer end-terminal motif-dependent evasion of human complement" (Nature Communications, 2021). With over 7,200 citations on Google Scholar, Simberg's contributions have advanced understanding of nanoparticle biocompatibility, influencing safer designs for nanomedicines used in imaging and therapy.